We are looking to expand our product platform by exploring the development of additional indications (including orphan indications), developing a biomarker to be able to identify earlier signs of CAVS, developing next generation technologies, and licensing and/or acquiring additional complementary intellectual property and technologies
Copyright © 2021 RSF Bio - All Rights Reserved.